Dr. Michael Gray is a
Senior Researcher in Clinical Therapeutic Ultrasound. He received a Ph.D.
degree in mechanical engineering from the Georgia Institute of Technology,
Atlanta, GA, USA, in 2015. From 1992 to 2015, he was a Research Engineer with
the Georgia Institute of Technology. In 2015, he joined the Biomedical
Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) group,
Institute of Biomedical Engineering, University of Oxford, Oxford, UK as the
lead engineer on a Phase 1 clinical trial of ultrasound-mediated targeted drug
delivery for treatment of liver cancer. Michael’s current research focuses on
three areas: (1) early-phase clinical trials of ultrasound-mediated drug delivery for the treatment of
abdominal organ cancers; (2) clinical
translation of quantitative cavitation monitoring techniques for non-invasive
treatment guidance, and (3) development of
devices to enable the use of sound, magnetism, and light for targeted drug
delivery.
Dr. Michael Gray is a
Senior Researcher in Clinical Therapeutic Ultrasound. He received a Ph.D.
degree in mechanical engineering from the Georgia Institute of Technology,
Atlanta, GA, USA, in 2015. From 1992 to 2015, he was a Research Engineer with
the Georgia Institute of Technology. In 2015, he joined the Biomedical
Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) group,
Institute of Biomedical Engineering, University of Oxford, Oxford, UK as the
lead engineer on a Phase 1 clinical trial of ultrasound-mediated targeted drug
delivery for treatment of liver cancer. Michael’s current research focuses on
three areas: (1) early-phase clinical trials of ultrasound-mediated drug delivery for the treatment of
abdominal organ cancers; (2) clinical
translation of quantitative cavitation monitoring techniques for non-invasive
treatment guidance, and (3) development of
devices to enable the use of sound, magnetism, and light for targeted drug
delivery.